OM
DNTH icon

Opaleye Management’s Dianthus Therapeutics DNTH Stock Holding History

Opaleye Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,525
Closed -$1.05M – 51
2021
Q1 		$1.05M Buy
5,525
+2,537
+85% +$427K 0.15% 55
2020
Q4 		$375K Buy
+2,988
New +$339K 0.05% 57
2020
Q3 		– Sell
-3,202
Closed -$385K – 61
2020
Q2 		$385K Sell
3,202
-23,968
-88% -$3.38M 0.08% 47
2020
Q1 		$2.73M Sell
27,170
-952
-3% -$176K 0.72% 31
2019
Q4 		$6.73M Buy
28,122
+4,059
+17% +$758K 1.32% 32
2019
Q3 		$3.95M Sell
24,063
-9,375
-28% -$1.78M 1.43% 29
2019
Q2 		$7.89M Buy
33,438
+1,563
+5% +$386K 2.41% 18
2019
Q1 		$8.4M Buy
31,875
+312
+1% +$53.8K 2.33% 16
2018
Q4 		$2.88M Sell
31,563
-13,750
-30% -$1.87M 1.07% 29
2018
Q3 		$8.71M Buy
45,313
+10,938
+32% +$2.3M 2.22% 12
2018
Q2 		$7.42M Buy
+34,375
New +$7.76M 1.92% 17

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management's DNTH Position: Q2 2021 in Review

Opaleye Management sold out of Dianthus Therapeutics (DNTH) in Q2 2021, closing a stake of 5,525 shares — an estimated $1.05M sold.

Opaleye Management first reported a position in DNTH in Q2 2018 and held it in 11 quarters. The position peaked at $8.71M in Q3 2018. 97 funds tracked by Wall St. Rank hold DNTH as of Q2 2021.

  • Opaleye Management reported no remaining Dianthus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Opaleye Management sold 5,525 Dianthus Therapeutics shares in Q2 2021, an estimated $1.05M.
  • Opaleye Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 11 quarters.
  • Opaleye Management's Dianthus Therapeutics position peaked at $8.71M in Q3 2018.
  • 97 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.